Protocol of the STRIDE-X study: a multicenter, single-arm trial of single tremelimumab regular interval durvalumab followed by hepatectomy for initially unresectable hepatocellular carcinoma
Authors:
Preprint
- 4 September 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
Background Hepatocellular carcinoma (HCC) ranks as the fifth most common cancer globally and the third leading cause of cancer-related death. Systemic therapies such as lenvatinib or the combination of atezolizumab and bevacizumab has recently emerged as a first-line therapy for advanced HCC. The introduction of tremelimumab with durvalumab (STRIDE regimen) has shown potential in improving overall survival in unresectable cases, making them candidates for surgical intervention post-treatment. Methods The STRIDE-X study is a prospective multicenter, single-arm trial aimed at evaluating the efficacy of single dose tremelimumab combined with durvalmub followed by hepatectomy in patients with initially unresectable HCC. This non-randomized, open-label study will enroll subjects based on specific inclusion criteria such as body weight over 30 kg, life expectancy of at least 12 weeks, and no prior treatments for HCC. Key exclusion criteria include significant cardiovascular disease, other active malignancies, and recent history of severe infections. Patients will undergo initial intravenous doses of tremelimumab and durvalumab, followed by an assessment of resectability via imaging after 8 and 16 weeks. If tumors become resectable, surgery will be scheduled for 3 to 8 weeks after the last dose of treatment. The primary endpoint is the safety of surgical resection post-therapy, measured by the incidence of Clavien-Dindo grade III or higher complications. Secondary endpoints include surgical resection rates, post-hepatectomy liver failure, progression-free survival (PFS), and overall survival (OS). Exploratory endpoint analyses will be conducted to further explore the potential biological markers, including plasma cytokines, PD-L1, PD-1, CTLA-4, and circulating tumor DNA (ctDNA). Discussion This study will aim to elucidate the safety of conversion surgery with STRIDE regimen for initially unresectable HCC. In addition, efficacy (PFS and OS), the conversion rate during the treatment course, and the analysis of relevant biomarkers will also be assessed. Trial registration This study is registered in the Japan Registry of Clinical Trials (jRCTs071250043, July 14, 2025).Keywords
All Related Versions
This publication has 13 references indexed in Scilit:
- Multicenter prospective study to evaluate the efficacy of lenvatinib to achieve conversion surgery for initially unresectable hepatocellular carcinoma: LENS-HCC trial.Journal of Clinical Oncology, 2022
- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.Journal of Clinical Oncology, 2022
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 updateJournal of Hepatology, 2021
- Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunityNature Cancer, 2021
- Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody CombinationsLiver Cancer, 2021
- Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 updateHepatology Research, 2019
- Does response rate of chemotherapy with molecular target agents correlate with the conversion rate and survival in patients with unresectable colorectal liver metastases?: A systematic reviewEuropean Journal of Surgical Oncology, 2017
- Hepatocellular carcinoma: a reviewJournal of Hepatocellular Carcinoma, 2016
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2009
- Classification of Surgical ComplicationsAnnals of Surgery, 2004